About Purine nucleoside phosphorylase LACC1
Purine nucleoside phosphorylase LACC1 (LACC1) is a protein
from Homo sapiens identified by UniProt accession
Q8IV20, 430 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Purine nucleoside phosphorylase LACC1 |
| UniProt accession | Q8IV20 |
| Gene | LACC1 |
| Organism | Homo sapiens |
| Length | 430 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (64)
Diseases linked to this target (Open Targets).
- juvenile arthritis due to defect in LACC1 · score 0.64
- Crohn's disease · score 0.45
- leprosy · score 0.44
- psoriasis · score 0.39
- inflammatory bowel disease · score 0.38
- systemic juvenile idiopathic arthritis · score 0.37
- asthma · score 0.37
- Behcet's syndrome · score 0.30
- ulcerative colitis · score 0.30
- ankylosing spondylitis · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IV20-F1 | alphafold | PREDICTED | 88.72 | — |
Amino-acid sequence (430 residues)
MAEAVLIDLF GLKLNSQKNC HQTLLKTLNA VQYHHAAKAK FLCIMCCSNI SYERDGEQDN CEIETSNGLS ALLEEFEIVS CPSMAATLYT IKQKIDEKNL SSIKVIVPRH RKTLMKAFID QLFTDVYNFE FEDLQVTFRG GLFKQSIEIN VITAQELRGI QNEIETFLRS LPALRGKLTI ITSSLIPDIF IHGFTTRTGG ISYIPTLSSF NLFSSSKRRD PKVVVQENLR RLANAAGFNV EKFYRIKTHH SNDIWIMGRK EPDSYDGITT NQRGVTIAAL GADCIPIVFA DPVKKACGVA HAGWKGTLLG VAMATVNAMI AEYGCSLEDI VVVLGPSVGP CCFTLPRESA EAFHNLHPAC VQLFDSPNPC IDIRKATRIL LEQGGILPQN IQDQNQDLNL CTSCHPDKFF SHVRDGLNFG TQIGFISIKE
Explore Purine nucleoside phosphorylase LACC1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets